Infertility & reduced fertility
Studies have associated U. urealyticum infection with reduced sperm motility, abnormal sperm morphology and impaired semen quality[9]. In women, Ureaplasma has been implicated in tubal-factor infertility through chronic low-grade inflammation[6]. While not every carrier becomes infertile, for couples already struggling to conceive these organisms are a treatable variable worth ruling out[4].
Pregnancy complications
Ureaplasma species can ascend from the lower genital tract into the amniotic cavity. They are one of the most frequently isolated organisms in cases of chorioamnionitis and have been linked to:
- Preterm premature rupture of membranes (PPROM)[3]
- Spontaneous preterm birth[7]
- Recurrent miscarriage in some cohorts[7]
- Low birth weight[3]
Neonatal disease
Babies can be colonised in utero or during delivery. In preterm neonates, Ureaplasma is associated with congenital pneumonia, bacteraemia, meningitis, and bronchopulmonary dysplasia — a chronic lung condition that can have lifelong consequences[1][2].
Urethritis & urogenital symptoms
In men, U. urealyticum is a recognised cause of non-gonococcal, non-chlamydial urethritis, particularly at higher bacterial loads[8][12]. Symptoms — when they appear — can include burning on urination, urethral discharge, or low-grade discomfort that recurs without obvious cause. In women, symptoms (when present) may include unusual discharge, dyspareunia, or chronic pelvic discomfort.
Pelvic inflammatory disease & chronic pain
Together with Mycoplasma hominis, Ureaplasma has been implicated in pelvic inflammatory disease (PID), bacterial vaginosis–associated inflammation, and chronic pelvic pain[6][10].
Other reported associations
- Post-partum and post-abortal endometritis[1]
- Reactive arthritis (rare, immunocompromised hosts)[6]
- Rare extragenital disease in immunosuppressed patients[2]
Antibiotic resistance — a real and growing concern
Ureaplasma lacks a cell wall, so beta-lactam antibiotics (penicillins, cephalosporins) do not work. Treatment relies on doxycycline, azithromycin or fluoroquinolones, and resistance to all three classes is rising globally[5]. That makes early detection — before resistance complicates treatment — more, not less, important.